Skip to main content
Premium Trial:

Request an Annual Quote

In Review: Petricoin & Liotta, Core Lab Directors, PGx, and PerkinElmer


Five years ago, Genome Technology ran a story that told the first half of the saga behind Emanuel Petricoin and Lance Liotta’s foray into generating a biomarker consisting of many proteins, called a proteomic fingerprint. Teaming with bioinformatics company Correlogic Systems to push their idea forward, the two were later accused of improper conduct for their simultaneous consulting work for a Correlogic competitor. The two continue their work in protein biomarkers as co-directors of the center for Applied Proteomics and Molecular Medicine at George Mason University and co-founders of Theranostics Health, which uses reverse phase protein microarrays for biomarker discovery.

In that same issue, a survey of core lab directors looked at hurdles involved in running a successful facility. Directors offered advice to their peers, including: widen the user base, get creative when it comes to funding new equipment, and learn how to talk to pushy clients. This month, GT features a survey that aims to find the best — and worst — of the core labs out there. We surveyed readers in academia, pharma, and biotech to find out how satisfied they are with their results and how accessible the latest technology is.

The February 2003 cover story featured Peter Coggins, who had recently been named president of PerkinElmer’s Life and Analytical Sciences business. At the time, his mission was to improve PE’s customer focus and diversify its product line to include more functional biology tools. A year later, Coggins was appointed to the US Department of Health & Human Services Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Over the past several years, PE has made headway in its biomarker discovery and high-throughput screening products.

A year ago, our cover story delved into translational medicine — what it is and why it’s here to stay. “The push to drag research from basic labs to the clinic has never been bigger,” the article said, and researchers continue to make inroads. GT interviewed Michael Phillips, director of pharmacogenomics at Genome Quebec and the Montreal Heart Institute, who, along with his colleague Jean-Claude Tardif, recently received a grant of $5 million to develop the infrastructure to conduct pharmacogenomic clinical trials both in Quebec and abroad.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.